Tangeretin alleviates sepsis-induced acute lung injury by inhibiting ferroptosis of macrophage via Nrf2 signaling pathway by Hui Zhang, Yan Wang, Shenghua Wang, Xiaomei Xue, Kai Huang, Dunfeng Xu, Lai Jiang, Siyuan Li, Yunqian Zhang

“…Tangeretin was applied intraperitoneally 30 min before LPS treatment. Dexamethasone (Dex) was used as a positive control. Hematoxylin and eosin (HE) staining and protein content in bronchoalveolar lavage fluid (BALF) were determined to detect the degree of lung injury. …”
Get full text

Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myeloma by Ka-Won Kang, Dae Sik Kim, Se Ryeon Lee, Mi Hwa Heo, Hyeon-Seok Eom, Jongheon Jung, Ji Hyun Lee, Sung-Hyun Kim, Youngil Koh, Chang-Ki Min, Seung Shin Lee, Sung-Nam Lim, Ho-Young Yhim, Myung-won Lee, Je-Jung Lee, Sung-Hoon Jung, Soo-Mee Bang, Kihyun Kim, the Korean Multiple Myeloma Working party [KMMWP]

“…Methods To determine whether maintenance therapy confers a survival benefit in the real world, we compared treatment outcomes according to the use and type of maintenance therapy in patients who underwent ASCT following frontline therapy with the triplet regimen of bortezomib, thalidomide, and dexamethasone for newly diagnosed multiple myeloma in 15 nationwide centers. …”
Get full text

Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial by Omar Nadeem, Michelle P. Aranha, Robert Redd, Michael Timonian, Sophie Magidson, Elizabeth D. Lightbody, Jean-Baptiste Alberge, Luca Bertamini, Ankit K. Dutta, Habib El-Khoury, Mark Bustoros, Jacob P. Laubach, Giada Bianchi, Elizabeth O’Donnell, Ting Wu, Junko Tsuji, Kenneth C. Anderson, Gad Getz, Lorenzo Trippa, Paul G. Richardson, Romanos Sklavenitis-Pistofidis, Irene M. Ghobrial

“…The single-arm I-PRISM phase II trial (NCT02916771) evaluated ixazomib, lenalidomide, and dexamethasone in 55 patients with HR-SMM. The primary endpoint, median progression-free survival (PFS), was not reached (NR) (95% CI: 57.7–NR, median follow-up 50 months). …”
Get full text

Impact of corticosteroids on the efficacy of CD19/22 CAR-T cell therapy in pediatric patients with B-ALL: a single-center study by Jing Yang, Jing Zhang, Xinyu Wan, Jiaoyang Cai, Jiaoyang Cai, Tianyi Wang, Xiaomin Yang, Wenjie Li, Lixia Ding, Lili Song, Yan Miao, Xiang Wang, Yani Ma, Chengjuan Luo, Jingyan Tang, Longjun Gu, Jing Chen, Jun Lu, Yanjing Tang, Benshang Li

“…The median cumulative dexamethasone-equivalent dose was 0.56 mg/kg, and the EFS and OS were similar in the different cumulative dose groups. …”
Get full text

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III... by Roger Owen, John Jones, David Meads, David A Cairns, Christopher Parrish, Gordon Cook, Neil Rabin, Matthew Jenner, Martin Kaiser, Kevin Boyd, Graham Jackson, Catherine Olivier, Amy Beth Coulson, Kara-Louise Royle, Charlotte Pawlyn, Anna Hockaday, Jennifer Bird, Stella Bowcock, Ruth de Tute, Hayley Gardner, Bryony Dawkins, Rowena Henderson, Phillip Best, Bhuvan Kishore, Mark Drayson

“…Research is required in this patient group, taking into account frailty and aiming to improve: treatment tolerability, clinical outcomes and quality of life.Methods and analysis Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma is a national, phase III, multicentre, randomised controlled trial comparing standard (reactive) and frailty-adjusted (adaptive) induction therapy delivery with ixazomib, lenalidomide and dexamethasone (IRD), and to compare maintenance lenalidomide to lenalidomide+ixazomib, in patients with newly diagnosed multiple myeloma not suitable for stem cell transplant. …”
Get full text

Identifying subgroup of severe community-acquired pneumonia based on clinical metagenomics, a multicenter retrospective cohort study by Mingqiang Wang, Mingqiang Wang, Yue Jin, Yue Jin, Wenxiao Zhang, Wenxiao Zhang, Ling Ye, Ling Ye, Huanzhang Shao, Huanzhang Shao

“…Additional analysis showed that in class B, methylprednisolone was associated with reduced mortality (adjusted HR=0.61; 95% CI, 0.44–0.86; p=0.005), while dexamethasone was not associated with mortality (adjusted HR=1.4; 95% CI, 0.89–2.22; p=0.148). …”
Get full text

Clinical management of community-acquired meningitis in adults in the UK and Ireland in 2017: a retrospective cohort study on behalf of the National Infection Trainees Collaborativ... by Amy Robinson, Kamaljit Khalsa, Arjun Chandna, John Bowen, Viva Levee, Jan Coebergh, Tom Solomon, Clive Graham, David Turner, Robert Tilley, Tim Jones, Susan Hopkins, Matthew Stevens, Daniel White, Celestine Eshiwe, Anna Goodman, Ramandeep Singh, Robert S Heyderman, Nicholas Davies, Joseph Thompson, Ed Moran, Martin Williams, Rhea O’Regan, Simon Tiberi, Jonathan Lambourne, Naomi Bulteel, Susan Larkin, Ruth McEwen, Hassan Paraiso, Aarti Shah, Martin Wiselka, Sylviane Defres, Ernest Mutengesa, Maria Krutikov, Ruth Owen, David Griffith, David Harvey, Trupti Patel, Brendan Davies, Emma Mclean, Joanna Allen, Ali Khan, Alastair Miller, Ashutosh Deshpande, Christopher Green, Lewis Jones, Mark Melzer, Fiona McGill, Amanda Fife, Nimal Wickramasinghe, Stephanie Harris, Ewan Hunter, Jayne Ellis, Benedict Rogers, Imogen Fordham, Elen Vink, Victoria Ward, Anna Smith, Andrew Rosser, Alison Muir, Ken Woodhouse, John Shone, Iain Crossingham, Ryan Jayesinghe, Eavan Muldoon, Avneet Shahi, Terry John Evans, Jeremy Wong, Eloisa MacLachlan, Amy Chue, Karishma Gokani, Katherine Ajdukiewicz, Lucinda Barrett, Frances Edwards, Adam Usher, Mairi McLeod, Su su Htwe, Grace Duane, Nicholas Wong, Jennifer Poyner, Jenni Crane, Ollie Lloyd, Emma Chisholm, Ildiko Kustos, Sam Sutton, M. Estee Torok, Isobel Ramsay, Monica Ivan, Joshua York, Jennifer Ansett, Maithili Varadarajan, Priya Sekhon, James Cruise, Shivani Kanabar, Mirella Ling, Charlotte Milne, Jayanta Sarma, Aline Wilson, Lynn Urquhart, Sahar Eldirdiri, Leila White, Jody Aberdein, Phillip Simpson, Hnin Hay Mar, Keying Tan, Eint Shwe Zin thein, Mahmoud Aziz, Anthony Cadwgan, Natasha Weston, Salman Zeb, Angela Houston, Louise Wootton, Iona Willingham, Aimee Johnson, Ashley Horsley, Eamonn Trainor, Olivier Gaillemin, Nicholas J Norton, Katie Cheung, Megan Duxbury, Emilie Bellhouse, Helena Brezovjakova, Kanitkar Tanmay, Alexsander Dawidziuk, Razan Saman, Hugh Adler, Elshadai Ejere, Yiwen Soo, Wendy Beadles, Heather Sturgeon, Brodie Cameron, David Chadwick Ben Tomlinson, Claire McGoldrick, Katie McDowell, Mpho Molosiwa, Katherine FlackAdrian Kennedy, Phoebe Cross, Fay Perry, Vithusha Inpadhas, Sarathy Selvam, Vhairi Bateman, Henry Wu, Monika Pasztor, Ajanthiha Karunakaran, Basma Soliman, Andrew Blanshard, Harish Reddy, Helen Chesterfield, Ben Schroeder, Tee Keat Teoh, Sathyavani Subbarao, Caryn RosmarinLucy Bell, Emma McGuire, Robert Serafino, Ishaan Bhide, Karanjeet Sagoo, Indran Balakrishnan, Kajal Patel, Barzo Faris, Graeme Calver, Ricky Singh, Hazel Sanghvi, Mohamed Eltayeb, Rathur Haris

“…Among those with bacterial meningitis, pneumococcal aetiology, admission to intensive care and initial Glasgow Coma Scale Score less than 14 were associated with in-hospital mortality (adjusted OR (aOR) 2.08, 95% CI 0.96 to 4.48; aOR 4.28, 95% CI 1.81 to 10.1; aOR 2.90, 95% CI 1.26 to 6.71, respectively). Dexamethasone therapy was weakly associated with a reduction in mortality in both those with proven bacterial meningitis (aOR 0.57, 95% CI 0.28 to 1.17) and with pneumococcal meningitis (aOR 0.47, 95% CI 0.20 to 1.10).Conclusion This study demonstrates that clinical care for patients with meningitis in the UK is not in line with current evidence-based national guidelines. …”
Get full text